

May, 23, 2013

---

### **MPH Mittelständische Pharma Holding AG:**

#### **1<sup>st</sup> Quarter 2013: +31.4% in Sales; +34.3% in EBIT**

For the first three months of the current year, the Group is reporting sales of EUR 53.42 million, with thus representing an increase of 31.4 % compared to the same period of the previous year (prior-year period: EUR 40.66 million). The consolidated profit before interests and taxes (EBIT) for January through March 2013, at EUR 4.15 million, was 34.3 % above the prior-year level (EUR 3.09 million). An EBIT margin of 7.8% was achieved.

#### **About MPH Mittelständische Pharma Holding AG:**

The company MPH Mittelständische Pharma Holding AG, based in Berlin, has strategically concentrated its activities on growth segments Pharma and Healthcare. On the basis of patent-free and patent-protected active substances, production and consultancy services for therapies of chronic diseases, the Group makes a precious contribution to keeping health affordable.

MPH Mittelständische Pharma Holding AG is listed in the Entry Standard (Open Market) of the Frankfurt stock exchange.

Key figures for the share of MPH Mittelständische Pharma Holding AG:

Subscribed capital: EUR 41.167.155

Listed shares: Preference shares

Number of preference shares in circulation: 19.025.000

ISIN: DE000A0NF697

WKN: A0NF69

Stock symbol: 93MV

#### **Contact:**

MPH Mittelständische Pharma Holding AG  
Linda Reichelt  
Fasanenstraße 77  
D-10623 Berlin

Tel.: +49 (0) 30 897 30 86 60  
Fax: +49 (0) 30 897 30 86 70

E-Mail: [ir@mph-ag.de](mailto:ir@mph-ag.de)  
Web: [www.mph-ag.de](http://www.mph-ag.de)